SLG
Stanley-Laman Group Portfolio holdings
AUM
$673M
This Quarter Return
+5.38%
1 Year Return
+14.64%
3 Year Return
+60.49%
5 Year Return
+79.33%
10 Year Return
+186.95%
AUM
$407M
AUM Growth
+$407M
(-8.6%)
Cap. Flow
-$50.7M
Cap. Flow
% of AUM
-12.45%
Top 10 Holdings %
Top 10 Hldgs %
19.3%
Holding
282
New
19
Increased
67
Reduced
110
Closed
63
Top Buys
| 1 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$7.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$7.16M |
| 3 |
Iovance Biotherapeutics
IOVA
|
$4.24M |
| 4 |
ALBO
Albireo Pharma, Inc. Common Stock
ALBO
|
$1.08M |
| 5 |
Zymeworks
ZYME
|
$887K |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$8.83M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$5.78M |
| 3 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$4.57M |
| 4 |
Sangamo Therapeutics
SGMO
|
$1.53M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$966K |
Sector Composition
| 1 | Industrials | 20.92% |
| 2 | Technology | 18% |
| 3 | Healthcare | 15.75% |
| 4 | Materials | 7.84% |
| 5 | Financials | 7.36% |